Literature DB >> 12163580

Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.

Kazuhiro Kakimi1, Masanori Isogawa, JoSan Chung, Alessandro Sette, Francis V Chisari.   

Abstract

Persistent hepatitis B virus (HBV) infection is characterized by a weak and narrowly focused CD8+ T-cell response to HBV that is thought to reflect the induction of central and/or peripheral tolerance to HBV proteins in neonatal and adult onset infections, respectively. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may lead to viral clearance in chronically infected individuals. The present study was performed to compare the relative immunogenicities and tolerogenicities of HBV structural (envelope [ENV]) and nonstructural (polymerase [POL]) proteins at the CD8+ cytotoxic T lymphocyte (CTL) level in transgenic mice that replicate HBV in the liver and secrete infectious virus into the blood, thus representing an excellent model of persistent HBV infection. Interestingly, the mice were tolerant to the ENV but not to the POL proteins at the CTL level. Furthermore, the POL-specific CTLs had no impact on HBV replication or liver function in vivo, even though they were readily induced and reached the liver after DNA immunization, reflecting their relatively low avidity and the low level at which the POL protein is expressed by the hepatocyte. Collectively, these results suggest that the factors that make POL less tolerogenic also make POL-specific CTLs relatively inefficient effector cells when they reach the target organ. Immunotherapeutic strategies to control HBV infection by inducing virus-specific CTL responses in chronically infected subjects should be evaluated in light of this observation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163580      PMCID: PMC136410          DOI: 10.1128/jvi.76.17.8609-8620.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Determination of lymphocyte division by flow cytometry.

Authors:  A B Lyons; C R Parish
Journal:  J Immunol Methods       Date:  1994-05-02       Impact factor: 2.303

2.  Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo.

Authors:  K Ando; L G Guidotti; S Wirth; T Ishikawa; G Missale; T Moriyama; R D Schreiber; H J Schlicht; S N Huang; F V Chisari
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

3.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules.

Authors:  J Ruppert; J Sidney; E Celis; R T Kubo; H M Grey; A Sette
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

4.  The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo.

Authors:  L Huang; G Soldevila; M Leeker; R Flavell; I N Crispe
Journal:  Immunity       Date:  1994-12       Impact factor: 31.745

5.  Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein.

Authors:  M Shirai; T Akatsuka; C D Pendleton; R Houghten; C Wychowski; K Mihalik; S Feinstone; J A Berzofsky
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

Review 6.  Hepatitis B virus immunopathogenesis.

Authors:  F V Chisari; C Ferrari
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

7.  DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.

Authors:  M L Michel; H L Davis; M Schleef; M Mancini; P Tiollais; R G Whalen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

8.  Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.

Authors:  S Wirth; L G Guidotti; K Ando; H J Schlicht; F V Chisari
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

9.  The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.

Authors:  B Rehermann; P Fowler; J Sidney; J Person; A Redeker; M Brown; B Moss; A Sette; F V Chisari
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

10.  Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope.

Authors:  J T Safrit; C A Andrews; T Zhu; D D Ho; R A Koup
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  45 in total

Review 1.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice.

Authors:  Tong-Dong Shi; Yu-Zhang Wu; Zheng-Cai Jia; Wei Zhou; Li-Yun Zou
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

3.  Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.

Authors:  Yuan Hong; Yibing Peng; Michael Mi; Haiyan Xiao; David H Munn; Gui-Qiang Wang; Yukai He
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

Review 4.  Resistance to lamivudine therapy: is there more than meets the eye?

Authors:  G Dusheiko; A Bertoletti
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

5.  Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro.

Authors:  M Shi; S Qian; W-W Chen; H Zhang; B Zhang; Z-R Tang; Z Zhang; F-S Wang
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

6.  Depletion of CD25+CD4+T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization.

Authors:  Yoshihiro Furuichi; Hirotake Tokuyama; Satoshi Ueha; Makoto Kurachi; Fuminori Moriyasu; Kazuhiro Kakimi
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

7.  In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance.

Authors:  Andrea Annoni; Brian D Brown; Alessio Cantore; Lucia Sergi Sergi; Luigi Naldini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

8.  MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs.

Authors:  Giovanni Sitia; Masanori Isogawa; Matteo Iannacone; Iain L Campbell; Francis V Chisari; Luca G Guidotti
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

9.  Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.

Authors:  Michael D Robek; Mayra L Garcia; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Immune effectors required for hepatitis B virus clearance.

Authors:  Priscilla L Yang; Alana Althage; Josan Chung; Holly Maier; Stefan Wieland; Masanori Isogawa; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.